(IN BRIEF) Sanofi’s Consumer Healthcare business unit (CHC) has introduced the Shared Care Collective, an advisory board consisting of experts from various fields, both internal and external, to bolster sustainability efforts within the CHC business. This initiative aims to foster … Read the full press release
(IN BRIEF) In a significant development, the second investigational Phase 3 trial of Dupixent® (dupilumab) for chronic obstructive pulmonary disease (COPD), known as NOTUS, has demonstrated promising results. The trial found that Dupixent reduced COPD exacerbations by 34% compared to … Read the full press release
Posted in Business, Education, France, Healthcare, Management, News, Pharma & Biotech, Science, Technology
Tagged COPD, Dupixent, Exacerbations, George D. Yancopoulos, Naimish Patel, NOTUS, Regeneron, Sanofi
(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release
Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged Anti-TL1As, Crohn's disease, in $1.5 Billion Deal, Inflammatory Bowel Disease Treatment, partnership, Paul Hudson, Richard Francis, Sanofi, sustainability, Teva, TEV’574, Ulcerative colitis, wellness
(IN BRIEF) Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli (ExPEC) that is currently in Phase 3 of clinical trials. ExPEC … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science
Tagged E. coli, E.mbrace, ExPEC, Janssen, partnership, Sanofi, SEPSIS, sustainability, Thomas Triomphe, vaccine
(IN BRIEF) The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO, a novel factor VIII replacement therapy used to control bleeding in patients with hemophilia A. ALTUVIIIO, also known as efanesoctocog alfa, stands out … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science
Tagged ALTUVIIIO, authorization, bleeding, Brian Foard, efanesoctocog alfa, FDA, hemophilia A, Japan, marketing, MHLW, partnership, Sanofi, Sobi, treatment
(IN BRIEF) Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO), and Sanofi have united to introduce ‘The Meningitis Flag,’ a worldwide campaign aimed at increasing awareness in the fight against meningitis. The campaign, supported by para-athletes including Ellie Challis, … Read the full press release
Posted in Business, Education, France, Healthcare, Management, Marketing, Media, News, Pharma & Biotech, Science, Sports
Tagged 'The Meningitis Flag', awareness, Confederation of Meningitis Organisations (CoMO), Davide Morana, Ellie Challis, Global Campaign, meningitis, Meningitis Research Foundation, Paris 2024 Paralympic Games, partnership, Paul Hudson, Sanofi, Théo Curin, vaccination, Vinny Smith
(NOTICIA EN BREVE) Sanofi ha nombrado a Elisabeth Moreno, exministra francesa de Igualdad de Género, Diversidad e Igualdad de Oportunidades, para su Junta de Diversidad, Equidad e Inclusión (DE&I) para los próximos tres años. El consejo asesor se creó en … Read the full press release
Posted in Business, France, Management, Pharma & Biotech
Tagged Caroline Casey, Dell, derechos humanos, diversidad, Dr. Rohini Anand, Elisabeth Moreno, Emmanuel Macron, France Télécom, Hewlett Packard, igualdad de género, Igualdad de oportunidades, Junta DE&I, Lenovo, lucha contra la discriminación, nombramiento, Paul Hudson, Sanofi
(IN BRIEF) Sanofi has appointed Elisabeth Moreno, former French Minister for Gender Equality, Diversity and Equal Opportunities, to its Diversity, Equity and Inclusion (DE&I) Board for the next three years. The advisory council was created in 2022 to support Sanofi’s … Read the full press release
Posted in Business, France, Management, Pharma & Biotech
Tagged appointment, Caroline Casey, DE&I Board, Dell, diversity, Dr. Rohini Anand, Elisabeth Moreno, Emmanuel Macron, Equal opportunities, fight discrimination, France Télécom, gender equality, Hewlett Packard, human rights, Lenovo, Paul Hudson, Sanofi
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, United Kingdom
Tagged 7th annual European Patients as Partners®, biotechnology, Boehringer Ingelheim, Center for BME Health, clinical development, clinical research, Clinical Research conference, clinical trials, Community Engagement, CSL Behring, Deirdre BeVard, Diversity in Clinical Research, drug development, government, Health Equity, Healthcare, Hospital, Lundbeck, Medicine Development, Medicine Lifestyle, Medicines Development, Novartis, Patient Advocacy, Patient Centricity, Patient Communities, patient engagement, Patient Perspective, Patient Recruitment, Patient Retention, Patient Voice, Patients as Partners, Pharmaceutical, research and development, Sanofi, The Conference Forum, Thistle Hotel Marble Arch, Valerie Bowling
(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, News, Pharma & Biotech
Tagged AstraZeneca, Beyfortus, commercialization, contractual agreements, nirsevimab, partnership, Sanofi, Sobi, USA
(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release
(PRESS RELEASE) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that its Q4 2022 Memorandum for modelling purposes is now available on the “Investors” page of the company’s website. This … Read the full press release
(PRESSEMITTEILUNG) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert, hat bekannt gegeben, dass sein Memorandum für das 4. Quartal 2022 zu Modellierungszwecken jetzt auf der Seite „Investoren“ der Website … Read the full press release
(PRESSEMITTEILUNG) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat eine exklusive weltweite Kooperationsvereinbarung mit IGM Biosciences, Inc. (Nasdaq: IGMS), einem Biotechnologieunternehmen im klinischen Stadium, das sich auf … Read the full press release
(PRESS RELEASE) SANOFI, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced an exclusive worldwide collaboration agreement signed with IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and … Read the full press release
(PRESSEMITTEILUNG) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert , hat angekündigt, dass das Unternehmen auf seinem Immunology Investor Event, das am Dienstag, den 29. März ab 14:00 Uhr … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronisch entzündliche Erkrankungen, chronisch obstruktive Lungenerkrankung, COPD, dupilumab, Dupixent®, Immunologie, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetische Zytokine, TAILORED COVALENCY™, Typ-2-Entzündung
(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Bill Sibold, chronic inflammatory diseases, Chronic obstructive pulmonary disease, COPD, dupilumab, Dupixent, immunology, Immunology Investor Event, John Reed, NANOBODY®, Regeneron Pharmaceuticals, Sanofi, synthetic cytokines, Tailored Covalency®, type 2 inflammation
Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide Sanofi to leverage its next-generation mRNA platform to unlock … Read the full press release
Posted in Austria, Business, France, Healthcare, News, Pharma & Biotech
Tagged acne, acne vulgaris, acquisition, antigens, biotechnology, Cutibacterium acnes bacterium, microbiome, mRNA, ORI-001, Origimm Biotechnology GmbH, Sanofi, Sanya Selak, skin disease, skin immunology, skin microbiome, Thomas Triomphe, virulent skin microbiome
Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release
Posted in France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, anti-human thymocyte antibody preparation, anti-thymocyte globulin, belumosudil, biopharmaceutical company, cGVHD, chronic graft-versus-host disease, fibrotic diseases, General Medicines, Harlan Waksal M.D., hematopoietic stem cell mobilizer, immuno-oncology therapies, immunomodulating agent, immunosuppressive, Kadmon Holdings, Mozobil®, Olivier Charmeil, plerixafor, polyclonal, Rezurock™, Sanofi, systemic therapy, Thymoglobulin®, transformative therapies, transplant portfolio
(PRESS RELEASE) PARIS, 20-Jul-2021 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced fexinidazole approval by the US Food and Drug Administration (FDA) as the first all-oral treatment for both stages of the … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech
Tagged Central African Republic, Democratic Republic of Congo, DNDi, Dr Bernard Pécoul, Drugs for Neglected Diseases initiative, FDA, fexinidazole, HAT, Human African trypanosomiasis, Luc Kuykens, National Sleeping Sickness Programs, neuropsychiatric symptoms, parasitic disease, Sanofi, sleeping sickness, Trypanosoma brucei gambiense, tse-tse fly, US Food and Drug Administration, WHO, World Health Organization
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?